AMPE - Ampio Pharmaceuticals, Inc.

0.2526
0.043   16.865%

Share volume: 25
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$0.21
0.04
0.20%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
65.53%
3 Months
-2.13%
6 Months
75.17%
1 Year
9,255.56%
2 Year
9,255.56%
Key data
Stock price
$0.25
P/E Ratio 
N/A
DAY RANGE
$0.01 - $0.30
EPS 
N/A
52 WEEK RANGE
$0.00 - $0.30
52 WEEK CHANGE
$9,255.56
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$25
AVERAGE 30 VOLUME 
$104
Company detail
CEO: Michael A. Martino
Region: US
Website: ampiopharma.com
Employees: 20
IPO year: 2022
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ampio Pharmaceuticals, Inc. focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial. AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation, AP-019, an Inhaled Ampion treatment.

Recent news